GENOR BIOPHARMA HOLDINGS LTD
HKEX: 6998 (GENOR-B)
Kemas kini terakhir: 4 jam lalu3.81
0.06 (1.60%)
| Penutupan Terdahulu | 3.75 |
| Buka | 3.77 |
| Jumlah Dagangan | 682,000 |
| Purata Dagangan (3B) | 1,139,768 |
| Modal Pasaran | 1,998,819,712 |
| Harga / Pendapatan (P/E TTM) | 54.43 |
| Harga / Jualan (P/S) | 7.14 |
| Harga / Buku (P/B) | 1.47 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 26 Aug 2025 - 1 Sep 2025 |
| Margin Keuntungan | -24.87% |
| Margin Operasi (TTM) | 45.37% |
| EPS Cair (TTM) | -0.110 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.08% |
| Nisbah Semasa (MRQ) | 8.74 |
| Aliran Tunai Operasi (OCF TTM) | -121.98 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -30.34 M |
| Pulangan Atas Aset (ROA TTM) | -1.54% |
| Pulangan Atas Ekuiti (ROE TTM) | -4.52% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (HK) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | GENOR-B | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 3.5 |
| Osilator Teknikal | 4.0 |
| Purata | 0.75 |
Saham Serupa
| Stok | Modal Pasaran | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| GENOR-B | 2 B | - | 54.43 | 1.47 |
| ALPHAMAB-B | 10 B | - | 41.23 | 5.23 |
| LEPU BIO-B | 10 B | - | - | 12.92 |
| ABBISKO-B | 9 B | - | 57.20 | 3.83 |
| CSTONE PHARMA-B | 9 B | - | - | 23.87 |
| FRONTAGE | 2 B | - | 104.00 | 0.790 |
|
Genor Biopharma Holdings Ltd is a commercial-ready biopharmaceutical company focusing on developing and commercializing oncology and autoimmune drugs. The company is focused on therapeutic areas with substantial unmet medical needs in oncology, autoimmune, and other chronic diseases. Its key drug candidates include GB491 (lerociclib), a differentiated oral CDK4/6 inhibitor; GB221, a novel HER2 mAb drug candidate; geptanolimab (GB226), GB492, a STING agonist expected to exert synergistic effects in combination with GB226; GB242, an infliximab (Remicade) biosimilar; and GB223, a RANKL, and others. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 9.43% |
| % Dimiliki oleh Institusi | 30.30% |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |